Abstract
Senescent cells show a series of alterations, including a flat and enlarged morphology, increase in nonspecific acidic β- galactosidase activity, chromatin condensation, and changes in gene expression patterns. The onset and maintenance of senescence are regulated by two tumor suppressor proteins, p53 and Rb, whose expression is controlled by two distinct proteins, p19Arf and p16Ink4a, respectively, which are encoded by the cdkn2a locus. Transcription factor Jun dimerization protein 2 (JDP2) which binds directly to histones and DNA, inhibits the acetylation and methylation of core histones and of reconstituted nucleosomes that contain JDP2-recognition DNA sequences. JDP2-deficient mouse embryonic fibroblasts are known to be resistant to replicative senescence. Oxygen induces the expression of the JDP2 gene and JDP2 then inhibits the recruitment of polycomb repressive complexes (PRCs1 and 2) to the promoter of the gene encoding p16Ink4a, resulting in the inhibition of methylation of lysine 27 of histone H3. These findings suggest that chromatinremodeling factors, including the PRC complex controlled by JDP2, are important players in the senescence. The newly defined mechanisms that underlie the action of oxygen in the induction of JDP2 and cellular senescence are reviewed.
Keywords: JDP2, AP-1, oxidative stress, senescence, epigenetic control, p16Ink4a, p19Arf, mutations, apoptosis, nucleophosmin
Current Pharmaceutical Design
Title: Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Volume: 17 Issue: 22
Author(s): Shin-Wei Wang, Jiag-Ki Lee, Chia-Chen Ku, Shyh-Shin Chiou, Chen-Lung Steve Lin, Ming-Feng Ho, Deng-Chyang Wu and Kazunari K. Yokoyama
Affiliation:
Keywords: JDP2, AP-1, oxidative stress, senescence, epigenetic control, p16Ink4a, p19Arf, mutations, apoptosis, nucleophosmin
Abstract: Senescent cells show a series of alterations, including a flat and enlarged morphology, increase in nonspecific acidic β- galactosidase activity, chromatin condensation, and changes in gene expression patterns. The onset and maintenance of senescence are regulated by two tumor suppressor proteins, p53 and Rb, whose expression is controlled by two distinct proteins, p19Arf and p16Ink4a, respectively, which are encoded by the cdkn2a locus. Transcription factor Jun dimerization protein 2 (JDP2) which binds directly to histones and DNA, inhibits the acetylation and methylation of core histones and of reconstituted nucleosomes that contain JDP2-recognition DNA sequences. JDP2-deficient mouse embryonic fibroblasts are known to be resistant to replicative senescence. Oxygen induces the expression of the JDP2 gene and JDP2 then inhibits the recruitment of polycomb repressive complexes (PRCs1 and 2) to the promoter of the gene encoding p16Ink4a, resulting in the inhibition of methylation of lysine 27 of histone H3. These findings suggest that chromatinremodeling factors, including the PRC complex controlled by JDP2, are important players in the senescence. The newly defined mechanisms that underlie the action of oxygen in the induction of JDP2 and cellular senescence are reviewed.
Export Options
About this article
Cite this article as:
Wang Shin-Wei, Lee Jiag-Ki, Ku Chia-Chen, Chiou Shyh-Shin, Steve Lin Chen-Lung, Ho Ming-Feng, Wu Deng-Chyang and K. Yokoyama Kazunari, Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence, Current Pharmaceutical Design 2011; 17 (22) . https://dx.doi.org/10.2174/138161211797052394
DOI https://dx.doi.org/10.2174/138161211797052394 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Links Between Sleep Apnea and Chronic Kidney Disease
Current Respiratory Medicine Reviews Opioid-induced Cardioprotection
Current Pharmaceutical Design Inspired Nitric Oxide and Modulation of Oxidative Stress During Cardiac Surgery
Current Drug Safety Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Severe Hyponatremia and Other Electrolyte Disturbances Associated with Indapamide
Current Drug Safety ATP Synthesis Revisited: New Avenues for the Management of Mitochondrial Diseases
Current Pharmaceutical Design Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Quantitative Coronary Angiography: Back to the Past
Recent Patents on Medical Imaging Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19
Current Stem Cell Research & Therapy Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Bioactive Compounds for Effective Management of Drug-Resistant Tuberculosis
Current Bioactive Compounds Aortic Wave Velocity: A Noninvasive Method to Measure the Stiffness of Arteries and the Clinical Results of Supplements That Appear to Improve Arterial Stiffness
Current Aging Science The Many Antithrombotic Actions of Nitric Oxide
Current Drug Targets Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Diagnostic and Therapeutic Potentials of microRNAs in Heart Failure
Current Topics in Medicinal Chemistry Lone Atrial Fibrillation- A Diagnosis of Exclusion
Current Pharmaceutical Design Involvement of Cytokines and Inflammation in Catecholamine-Induced Pulmonary Injury in Rats
Vascular Disease Prevention (Discontinued) Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users
Current Pharmaceutical Design Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Current Pharmaceutical Design